The Myelodysplastic Syndromes (MDS) Foundation says a study published
this week in the Journal of Clinical Oncology concludes VIDAZA
(azacitidine) “prolongs survival and is well tolerated” in patients with
acute myeloid leukemia (AML) - an aggressive form of leukemia that in
many cases progresses from MDS. The study looked at older patients with
a median age of 70. These are patients who have had “no truly adequate
treatments,” however the study found that half of the patients treated
with VIDAZA survived at least two years, compared to only 16% of
patients who received conventional care. Nearly 13,000 AML patients are
diagnosed each year in the United States.
“This is encouraging news for patients with AML, an aggressive,
difficult to treat cancer where median survival is less than one year”
“This is encouraging news for patients with AML, an aggressive,
difficult to treat cancer where median survival is less than one year,”
said Kathy Heptinstall, Operating Director of the Myelodysplastic
Syndromes Foundation. “Currently, as documented by an editorial in the
same journal, a large portion of older AML patients are offered only
supportive or palliative care. We would hope that publication of these
encouraging results will spread the word and help change the approach to
treatment.”
The study also found that VIDAZA helped reduce the need for blood
transfusions that are often required in AML. 41% of patients on VIDAZA
achieved transfusion independence, compared to only 18% receiving
conventional care. VIDAZA treatment also significantly reduced the
number of days spent in the hospital, and reduced serious infections.
The findings come from a subset of an international study of VIDAZA that
previously demonstrated improved survival in patients with higher-risk
MDS. Both MDS and AML are malignant conditions of cells in the bone
marrow. Previously, the National Comprehensive Cancer Network
recommended VIDAZA and DACOGEN® as treatment
options for AML patients over 60 years old.